Affymetrix & eBioscience Amend Definitive Merger Agreement

Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to usual adjustments.

Affymetrix, Inc. and eBioscience, Inc. announced that they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience.

Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to usual adjustments. The transaction remains subject to customary closing conditions and is now expected to close late in the quarter ending June 30, 2012.

"The feedback from our customers, shareholders and partners has been consistently positive since we announced our original agreement with eBioscience last November," said Dr. Frank Witney, president and chief executive officer of Affymetrix. "By amending the transaction, we are now able to realize the benefits of combining